Personalized treatments for nausea and vomiting

Personalized treatments for nausea and vomiting

VJOncology

3 years
652 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Alex Molassiotis, RN, MSc, PhD of The Hong Kong Polytechnic University, Hong Kong, discusses personalized treatments for nausea and vomiting. Nausea and vomiting is a multifactorial problem and it is not always clear which factors are involved, therefore patients need to be evaluated in order to identify the risk. A following prescription of antiemetics based on that risk is then required, beyond just the antiemetics that are directly linked to managing chemotherapy related problems. Dr. Molassiotis provides a hypothetical example of a personalized treatment for nausea. He mentions that if the patient is young, very anxious and with a past experience of strong vomiting during pregnancy, those factors place her under a much higher risk. Therefore, in this example, the patient would need to be supported beyond the standard guidelines of three drug combination: 5-HT3 receptor antagonist, dexamethasone, and NK1 receptor antagonist. Lorazepam would be a necessary anti-anxiety drug to aid the existing treatment, or olanzapine if the patient experiences a lot of nausea. Dr Molassiotis example explains why these different risk factors need to be taken into consideration, adding some additional treatments to the standard combination. His overall message expresses how significant advances have been made in this area of supportive care, however, more progress is needed for the management of nausea, which is where the focus belongs presently and in the future. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 2 days
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 2 days
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 2 days
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
12 Views
ash 2 days
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 2 days
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
2 Views
ash 3 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 3 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
3 Views
ash 3 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 3 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 days